The global market for cell – based therapies is expected to surpass the $20 billion USD mark by 2025, with an annual growth rate of 21%. The main targets for cell – based therapies are high impact disease areas with significant unmet needs, including cancer, heart disease, neurodegenerative diseases, musculoskeletal disorders and autoimmune diseases.
As seen from the biotech industry, there is a dynamic balance of the global regulatory environment. Where does the tipping point/s lay? How does the Good Manufacturing Principles (GMP) in clinical trials play in that game? G&CT executives and other decision makers strive for a new therapy to succeed and another life to be saved. What is the cost-effectiveness rationale behind those scientific and business breakthroughs?
This whitepaper explores how the commercialization of cell and gene therapies is already underway and where it is going in the future.
To download the whitepaper simply log in or register for a KNect365 account, which will give you access to all our exclusive premium content.
Log in or Create an Informa Connect Account to Access this content
Creating an account also means you'll get special access to article updates and exclusive industry content.